AU2021327164A1 - Etoposide toniribate formulation - Google Patents

Etoposide toniribate formulation Download PDF

Info

Publication number
AU2021327164A1
AU2021327164A1 AU2021327164A AU2021327164A AU2021327164A1 AU 2021327164 A1 AU2021327164 A1 AU 2021327164A1 AU 2021327164 A AU2021327164 A AU 2021327164A AU 2021327164 A AU2021327164 A AU 2021327164A AU 2021327164 A1 AU2021327164 A1 AU 2021327164A1
Authority
AU
Australia
Prior art keywords
pharmaceutical formulation
liquid pharmaceutical
etoposide
toniribate
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021327164A
Other languages
English (en)
Inventor
Davide GUGGI
Javier MARTÍNEZ RUBIO
Anna MONTES VÁZQUEZ
Rudy Thoma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellAct Pharma GmbH
Original Assignee
CellAct Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2012956.5A external-priority patent/GB202012956D0/en
Priority claimed from GBGB2012954.0A external-priority patent/GB202012954D0/en
Application filed by CellAct Pharma GmbH filed Critical CellAct Pharma GmbH
Publication of AU2021327164A1 publication Critical patent/AU2021327164A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021327164A 2020-08-19 2021-08-19 Etoposide toniribate formulation Pending AU2021327164A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2012954.0 2020-08-19
GBGB2012956.5A GB202012956D0 (en) 2020-08-19 2020-08-19 Etoposide toniribate formulation
GB2012956.5 2020-08-19
GBGB2012954.0A GB202012954D0 (en) 2020-08-19 2020-08-19 Etoposide toniribate formulation
PCT/EP2021/073034 WO2022038226A1 (en) 2020-08-19 2021-08-19 Etoposide toniribate formulation

Publications (1)

Publication Number Publication Date
AU2021327164A1 true AU2021327164A1 (en) 2023-03-16

Family

ID=80322580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021327164A Pending AU2021327164A1 (en) 2020-08-19 2021-08-19 Etoposide toniribate formulation

Country Status (7)

Country Link
US (1) US20230398069A1 (https=)
EP (1) EP4199933A1 (https=)
JP (1) JP2023539154A (https=)
KR (1) KR20230131815A (https=)
AU (1) AU2021327164A1 (https=)
CA (1) CA3189720A1 (https=)
WO (1) WO2022038226A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4233837A1 (en) * 2022-02-24 2023-08-30 CellAct Pharma GmbH Solid and oral etoposide toniribate compositions
CN116983259A (zh) * 2023-09-27 2023-11-03 成都瑞尔医药科技有限公司 一种依托泊苷注射液的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507233A (ja) * 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
AU2002358086B2 (en) * 2001-12-03 2009-06-04 Universitatsklinikum Charite Der Humboldt-Universitat Zu Berlin Technologie Transferstelle Podophyllotoxins as antiproliferative agents
JP4020256B2 (ja) * 2003-05-23 2007-12-12 日本化薬株式会社 前立腺癌の局所治療剤
JP2008543789A (ja) * 2005-06-17 2008-12-04 ホスピラ オーストラリア ピーティーワイ エルティーディー ドセタキセルの液体薬学的処方物
US9889147B2 (en) * 2010-04-16 2018-02-13 Cellact Pharma Gmbh Analogues of etoposide for the treatment of tumours
KR102122429B1 (ko) * 2011-04-28 2020-06-12 온코펩타이드즈 아베 세포독성 디펩티드의 동결건조 제제
DK2701720T3 (en) * 2011-04-28 2017-10-09 Oncopeptides Ab Lyophilized preparation with cytotoxic dipeptides
GB2513299A (en) * 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells

Also Published As

Publication number Publication date
KR20230131815A (ko) 2023-09-14
US20230398069A1 (en) 2023-12-14
JP2023539154A (ja) 2023-09-13
WO2022038226A1 (en) 2022-02-24
EP4199933A1 (en) 2023-06-28
CA3189720A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
EP3355881B1 (en) Oral taxane compositions and methods
PL197948B1 (pl) Trwały preparat roztworu oksaliplatyny i sposób wytwarzania trwałego roztworu oksaliplatyny
MXPA04005423A (es) Formulaciones farmaceuticas con derivado de platino.
TW200800159A (en) Pharmaceutical formulation
CN102781447B (zh) 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液
JP5334937B2 (ja) ビノレルビンを含むソフトカプセルのための経口製薬組成物及び治療方法
AU2021327164A1 (en) Etoposide toniribate formulation
EP2903435B1 (en) Non-aqueous taxane nanodispersion formulations and methods of using the same
CN104414977A (zh) 一种注射用青蒿琥酯和l-精氨酸组合物及其制备方法
WO2009043226A1 (en) A stable liquid composition comprising taxan derivatives and its preparation method.
CN103816126B (zh) 一种含有丁溴东莨菪碱的药物组合物
EP4482463A1 (en) Solid and oral etoposide toniribate compositions
CN114224832A (zh) 一种恩杂鲁胺注射剂及其制备方法和应用
CN107080748B (zh) 一种阿魏酸川芎嗪固体脂质纳米粒及其制备方法与应用
HK40109413A (zh) 一种普那布林胶束组合物及其制备方法
EP4603083A1 (en) Plinabulin micelle composition and preparation method therefor
RU2279873C2 (ru) Пероральная фармацевтическая композиция для мягких капсул, содержащая винорелбин, и способ лечения
US20160120742A1 (en) Compositions including cabazitaxel
CN102885823B (zh) 丹参酮iia磺酸钠的稳定药物组合物
CN105769757B (zh) 一种治疗非霍奇金淋巴瘤的注射液及其制备方法
CN103861113A (zh) 紫杉醇抗肿瘤制剂及其制备方法
CN111557934A (zh) 一种含多西他赛的药物组合物及其制备方法和用途
HK1112672B (en) Vinorelbine soft capsule, preparing method and use thereof
HK1112672A1 (en) Vinorelbine soft capsule, preparing method and use thereof
HK1210665B (en) Non-aqueous taxane nanodispersion formulations and methods of using the same